Tags

Type your tag names separated by a space and hit enter

Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV).
Viruses 2019; 11(9)V

Abstract

The US Food and Drug Administration issued a black box warning related to the risk of reactivation of overt/occult hepatitis B virus (HBV) infection during direct acting-antivirals (DAA) treatment. This review evaluated the prevalence of HBV reactivation after hepatitis C virus (HCV) pharmacological suppression and hypothesized the management and prevention of this reactivation. During and after DAA-based treatment, reactivation of HBV infection is common in patients with detectable serum HBsAg (from 2% to 57%) and very low (less than 3%) in individuals with isolated anti-HBc antibodies. The severity of hepatic damage may range from HBV reactivation without hepatitis to fulminant hepatic failure requiring liver transplantation. Thus, HBsAg-positive patients should receive nucleo(s)tide analog (NA) treatment or prophylaxis at the same time as DAA therapy. For those patients with occult B infection, there are no sufficient recommendations to start prophylactic treatment. Reactivation of overt or occult HBV infection during or after eradication of HCV infection is an issue to consider, and additional studies would help to determine the best management of this virological and clinical event.

Authors+Show Affiliations

Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania, 80138 Naples, Italy. meri.pisaturo@libero.it.Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania, 80138 Naples, Italy. macera.margherita@libero.it.Infectious Diseases Unit, AO Caserta, 81100 Caserta, Italy. loredana.alessio@gmail.com.Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania, 80138 Naples, Italy. fede.calo85@gmail.com.Laboratory for the identification of prognostic factors of response to the treatment against infectious diseases, University of Campania, 80138 Naples, Italy. nicola.coppola@unicampania.it. Infectious Diseases and Viral Hepatitis, Department of Mental and Physical Health and Preventive Medicine, University of Campania, 80138 Naples, Italy. nicola.coppola@unicampania.it. Infectious Diseases Unit, AO Caserta, 81100 Caserta, Italy. nicola.coppola@unicampania.it.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31540223

Citation

Pisaturo, Mariantonietta, et al. "Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV)." Viruses, vol. 11, no. 9, 2019.
Pisaturo M, Macera M, Alessio L, et al. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses. 2019;11(9).
Pisaturo, M., Macera, M., Alessio, L., Calò, F., & Coppola, N. (2019). Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses, 11(9), doi:10.3390/v11090850.
Pisaturo M, et al. Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). Viruses. 2019 Sep 13;11(9) PubMed PMID: 31540223.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hepatitis B Virus (HBV) Reactivation Following Pharmacological Eradication of Hepatitis C Virus (HCV). AU - Pisaturo,Mariantonietta, AU - Macera,Margherita, AU - Alessio,Loredana, AU - Calò,Federica, AU - Coppola,Nicola, Y1 - 2019/09/13/ PY - 2019/08/17/received PY - 2019/09/02/revised PY - 2019/09/10/accepted PY - 2019/9/22/entrez KW - HBV/HCV dual infection KW - HBsAg KW - occult HBV infection KW - occult HBV reactivation KW - overt HBV reactivation JF - Viruses JO - Viruses VL - 11 IS - 9 N2 - The US Food and Drug Administration issued a black box warning related to the risk of reactivation of overt/occult hepatitis B virus (HBV) infection during direct acting-antivirals (DAA) treatment. This review evaluated the prevalence of HBV reactivation after hepatitis C virus (HCV) pharmacological suppression and hypothesized the management and prevention of this reactivation. During and after DAA-based treatment, reactivation of HBV infection is common in patients with detectable serum HBsAg (from 2% to 57%) and very low (less than 3%) in individuals with isolated anti-HBc antibodies. The severity of hepatic damage may range from HBV reactivation without hepatitis to fulminant hepatic failure requiring liver transplantation. Thus, HBsAg-positive patients should receive nucleo(s)tide analog (NA) treatment or prophylaxis at the same time as DAA therapy. For those patients with occult B infection, there are no sufficient recommendations to start prophylactic treatment. Reactivation of overt or occult HBV infection during or after eradication of HCV infection is an issue to consider, and additional studies would help to determine the best management of this virological and clinical event. SN - 1999-4915 UR - https://www.unboundmedicine.com/medline/citation/31540223/Hepatitis_B_Virus_(HBV)_Reactivation_Following_Pharmacological_Eradication_of_Hepatitis_C_Virus_(HCV) L2 - http://www.mdpi.com/resolver?pii=v11090850 DB - PRIME DP - Unbound Medicine ER -